M&A: Page 2

  • A person holds up an N95 mask in front of a sign that says "SARS Clinic"
    Image attribution tooltip
    Don MacKinnon via Getty Images

    3M to spin out its healthcare business

    The decision comes amid spin-offs by several large medtech firms, including J&J and GE.

    By July 26, 2022
  • A doctor shines a light in a patient's eye.
    Image attribution tooltip
    seb_ra via Getty Images

    AbbVie agrees to pay $60M for rights to acquire implantable glaucoma device

    The biotech company said the deal is an opportunity to grow its eye-care business.

    By July 20, 2022
  • A staff member from McSwain Union Elementary School District in Merced, California participates in the district's voluntary COVID-19 testing pilot. Explore the Trendline
    Image attribution tooltip
    Permission granted by Roy Mendiola

    MedTech Dive Outlook 2022

    The pandemic continues to disrupt the medical device industry early in 2022, as COVID-19 testing demand remains strong and nonemergent procedures are postponed. In this series, we look at the risks, challenges and opportunities ahead.

    By MedTech Dive staff
  • Illumina fails to block EU antitrust review of $8B Grail merger

    By siding with the European Commission, the General Court has cleared the EU to resume a review that could lead to it blocking the deal and fining Illumina.

    By July 18, 2022
  • The CathWorks FFRangio System on a cart.
    Image attribution tooltip
    Permission granted by CathWorks

    Medtronic lands option to buy artery disease player CathWorks for up to $585M

    CathWorks has the right to compel Medtronic to complete the acquisition if it chooses not to exercise its option.

    By July 13, 2022
  • SEC under fire
    Image attribution tooltip
    Chip Somodevilla via Getty Images

    Ex-Mazor executive charged by SEC with insider trading over Medtronic's $1.6B buyout

    Doron Tavlin, who was Mazor’s vice president of business development, is accused by the agency of profiting from his inside knowledge of the pending takeover.

    By July 11, 2022
  • Image attribution tooltip
    Maks_Lab via Getty Images

    Medtech M&A falls 85% but activity could rebound in second half: report

    PwC highlights a range of barriers that could stop acquisitions, including supply chain issues, scrutiny from the Federal Trade Commission and geopolitical concerns.

    By June 24, 2022
  • A stock image of a calculator alongside financial numbers
    Image attribution tooltip
    atiatiati via Getty Images

    Bioventus agrees to staggered payment plan to close stalled $315M CartiHeal takeover

    Rising interest rates quashed a plan for Bioventus to fund the takeover of the joint repair company with a bond offering. Now, the deal will get much more expensive, J.P. Morgan analysts said.

    By June 23, 2022
  • Boston Scientific inks $230M deal to buy majority stake in M.I.Tech

    M.I.Tech is a South Korean manufacturer of endoscopic and urologic medical devices. Analysts at BTIG said the deal complements Boston Scientific’s non-vascular stent portfolio and boosts its international presence.

    By June 16, 2022
  • ResMed to acquire German health software company MediFox for $1B

    The acquisition continues a pattern of medical device companies buying software platforms. ResMed expects the deal to close by the end of the year.

    By Ricky Zipp • June 14, 2022
  • Oracle closes $28B buy of 'huge growth engine' Cerner

    With the deal’s close, the days of standalone EHR vendors are increasingly in the rearview mirror.

    By Rebecca Pifer • June 10, 2022
  • Becton Dickinson's headquarters, viewed from overhead, are surrounded by a green lawn.
    Image attribution tooltip
    Permission granted by Becton Dickinson

    BD to acquire Parata for $1.53B as part of strategy to boost margins

    The deal is expected to help Becton Dickinson reach its goal of a 25% operating margin by the end of 2025. J.P. Morgan analysts said it would be the most meaningful tuck-in deal since BD acquired Bard in 2017. 

    By June 7, 2022
  • Boston Scientific Watchman FLX left atrial appendage closure device
    Image attribution tooltip
    Courtesy of Boston Scientific

    Boston Scientific would be 'good fit' for increasingly acquisitive J&J, analysts say

    A limited portfolio overlap could make Boston Scientific a target should Johnson & Johnson's CEO seek a large medtech acquisition.

    By May 31, 2022
  • A view of Baxter International's production facility in the state of North-Rhine Wetsphalia on January 15, 2021 in Halle, Germany.
    Image attribution tooltip
    Sascha Schuermann via Getty Images

    Baxter raises forecasts for Hillrom synergies, allaying concerns over $10.5B takeover

    Company executives said the additional cost savings emerged as they took a closer look at Hillrom’s real estate footprint.

    By May 26, 2022
  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    Medtronic completes Intersect acquisition following FTC order

    The Federal Trade Commission required Medtronic to divest a subsidiary of Intersect ENT to complete the deal. Medtronic announced the $1.1 billion acquisition last August.

    By Updated May 16, 2022
  • $100 bills floating
    Image attribution tooltip
    choness via Getty Images

    Digital health funding dropped in Q1 to lowest level since 2020: CB Insights

    The report is directionally in line with the findings of an earlier report from Rock Health, which described how the drying up of deals in February and March may be an early sign of a correction in digital health venture capital funding.

    By April 14, 2022
  • Image attribution tooltip
    E+ via Getty Images

    'Interesting anomaly': Hospital M&A fell to record low in Q1

    Hospital M&A activity in the first quarter bucked last year's trends as both the amount and size of deals shrank, according to Kaufman Hall.

    By Hailey Mensik • April 11, 2022
  • Illumina sues Guardant CEOs over trade secrets, sparking counterblast against 'retaliatory' lawsuit

    Guardant called the lawsuit "frivolous and retaliatory" and framed it as a response to its concerns about the Illumina-Grail merger.

    By March 18, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive

    Akili plans to go public as it prepares to market video game treatment

    "We've proven that foundation and now it's time to run and scale," CEO Eddie Martucci told MedTech Dive. The company is going public through a $1 billion SPAC, rather than a traditional IPO, which it expects to close in mid-2022.   

    By March 10, 2022
  • DOJ moves forward with suit to block UnitedHealth's acquisition of Change

    The lawsuit alleges that if UnitedHealth acquired Change, the payer would be able to gain a competitive advantage by seeing "very competitively sensitive" data from other insurers.

    By Shannon Muchmore • Feb. 25, 2022
  • Johnson & Johnson's campus in Irvine, California
    Image attribution tooltip
    Mario Tama via Getty Images

    What does a more aggressive M&A approach mean for J&J's devices unit?

    After medical device deals took off last year, one of the industry's biggest companies could make a splash in the sector in 2022.

    By Ricky Zipp , Feb. 22, 2022
  • Closeup shot of two unrecognisable businesspeople shaking hands in an office
    Image attribution tooltip
    Delmaine Donson via Getty Images

    Diagnostics M&A expected to be strong in 2022 after dealmaking took off last year

    Respondents to KPMG's survey predict that deal volumes and values for the diagnostics space will jump again this year as companies are ready to spend more of their COVID-19 cash.

    By Feb. 16, 2022
  • Johnson & Johnson, credo wall
    Image attribution tooltip
    Permission granted by Johnson & Johnson

    J&J's DePuy Synthes buys ortho company CrossRoads Extremity Systems

    The deal, for an undisclosed amount, comes just weeks after Johnson & Johnson executives said the company will have a more aggressive M&A strategy going forward for the pharmaceutical and medical devices businesses.

    By Ricky Zipp • Feb. 10, 2022
  • An empty hospital operating theater is prepared with lighting and equipment
    Image attribution tooltip
    JohnnyGreig via Getty Images

    Healthcare staffing shortages a 'rising concern' for medtechs: Moody's

    In a recent quarterly report, Moody's Investors Service called out hospital labor shortages as having a potential material impact on procedures in 2022, even as the omicron surge begins to decline.

    By Feb. 9, 2022
  • Image attribution tooltip
    alvarez via Getty Images
    Deep Dive

    4 key trends for procedure-reliant medtechs in 2022

    Medical device companies likely will face the same challenges this year that they have been dealing with since the pandemic's start, such as procedure volatility and hospital staffing shortages.

    By Ricky Zipp • Jan. 27, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J's device recovery slowed by omicron surge, with impact expected over next several months

    CFO Joseph Wolk said that the medtech giant expects pressure from COVID-19 and hospital staffing shortages to continue through the first half of 2022, with businesses recovering month by month.

    By Ricky Zipp • Jan. 25, 2022